Hypoimmune, allogeneic CD19-directed CAR T-cell therapy engineered to evade host immune rejection and deplete CD19+ B-lineage cells to reset humoral immunity in autoimmune disease.
Allogeneic T cells engineered with an anti‑CD19 chimeric antigen receptor recognize and kill CD19+ B‑lineage cells (naive/memory B cells and plasmablasts), depleting pathogenic B cells to reset humoral immunity. The product is rendered 'hypoimmune' by disrupting MHC class I/II and overexpressing CD47 to evade host immune rejection and enhance persistence.
Anti‑CD19 CAR T cells bind CD19 on B-lineage cells, become activated, and lyse target cells via perforin/granzyme release and death receptor–mediated apoptosis.
Anti‑CD20 monoclonal antibody that depletes CD20+ B cells via antibody‑dependent cellular cytotoxicity, complement‑dependent cytotoxicity, and apoptosis.
Chimeric anti‑CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes CD20+ cells via antibody‑dependent cellular cytotoxicity, complement‑dependent cytotoxicity, and induction of apoptosis, reducing malignant B‑cell populations.
Binds CD20 on B cells and triggers Fc-mediated ADCC by NK/macrophages, complement-dependent cytotoxicity (CDC), and can induce apoptosis upon CD20 crosslinking.
Rituximab‑abbs biosimilar; anti‑CD20 monoclonal antibody that depletes CD20+ B cells via ADCC, CDC, and apoptosis.
Anti-CD20 monoclonal antibody (rituximab-abbs) that binds CD20 on B lymphocytes and depletes CD20+ B cells via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis.
Anti-CD20 mAb binds CD20 on B cells and kills via Fc-mediated ADCC by NK/macrophages, complement-dependent cytotoxicity (CDC), and can trigger apoptosis upon CD20 ligation.
Rituximab‑pvvr biosimilar; anti‑CD20 monoclonal antibody that depletes CD20+ B cells via ADCC, CDC, and apoptosis.
Ruxience (rituximab‑pvvr) is an anti‑CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes CD20+ B cells via antibody‑dependent cellular cytotoxicity (ADCC), complement‑dependent cytotoxicity (CDC), and induction of apoptosis.
Anti-CD20 antibody binds CD20 on B cells and triggers killing via antibody-dependent cellular cytotoxicity (effector cells), complement-dependent cytotoxicity, and direct apoptosis signaling.
Rituximab‑arrx biosimilar; anti‑CD20 monoclonal antibody that depletes CD20+ B cells via ADCC, CDC, and apoptosis.
Riabni (rituximab-arrx) is an anti-CD20 monoclonal antibody that binds CD20 on B cells and mediates B-cell depletion via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis.
Anti-CD20 mAb binds CD20 on B cells and induces killing via Fc-mediated ADCC, complement-dependent cytotoxicity (CDC), and can trigger apoptosis upon CD20 engagement.